The NIH entitlement program
Vincent T. DeVita, Jr
p613 | doi:10.1038/nrclinonc.2009.164
Current Issue
November 2009 Vol 6 No 11
Editorial
Research Highlights
Pathology: Protein kinase A predicts response to radiation and androgen deprivation therapy | PDF (155 KB)
p615 | doi:10.1038/nrclinonc.2009.154
Medical oncology: T-cell infiltrate predicts long-term survival in CRC | PDF (100 KB)
p616 | doi:10.1038/nrclinonc.2009.153
Micrometastases and breast cancer | PDF (48 KB)
p616 | doi:10.1038/nrclinonc.2009.157
Gefitinib efficacy in adenocarcinoma | PDF (48 KB)
p617 | doi:10.1038/nrclinonc.2009.151
Hematology: Hodgkin lymphoma survivors: high risk of stroke and TIA | PDF (47 KB)
p617 | doi:10.1038/nrclinonc.2009.152
Targeted therapies: Denosumab benefits men on long-term ADT | PDF (50 KB)
p617 | doi:10.1038/nrclinonc.2009.158
Hematology: Ipilimumab of benefit in unresectable melanoma | PDF (51 KB)
p618 | doi:10.1038/nrclinonc.2009.155
Pathology: Prostate cancer—personalized response prediction | PDF (51 KB)
p618 | doi:10.1038/nrclinonc.2009.156
News and Views
Imaging: PET–CT imaging in non-small-cell lung cancer
Mark Levine & Jim Julian
p619 | doi:10.1038/nrclinonc.2009.163
Imaging is performed in patients with early stage non-small-cell lung cancer (NSCLC) for disease staging and to identify the patients most likely to benefit from surgery. Two recent randomized trials compared conventional staging plus PET with conventional staging alone in patients with NSCLC. Patients who underwent PET were more likely to avoid futile thoracic surgery.
Chemotherapy: Adding oxaliplatin to the equation
Al B. Benson
p620 | doi:10.1038/nrclinonc.2009.162
Pooled analyses from the Adjuvant Treatment of Colon Cancer trial suggest that most patients with stage III colon cancer develop recurrence within the first 3 years following treatment. Improved disease-free survival and improved overall survival were observed for such patients who were treated with adjuvant combination therapy of 5-fluorouracil, leucovorin and oxaliplatin versus those treated with 5-fluorouracil and leucovorin.
Hematology: The case against rituximab maintenance
Bruce D. Cheson
p622 | doi:10.1038/nrclinonc.2009.161
The monoclonal antibody, rituximab, is used to treat lymphomas. This article discusses the results of randomized trials that suggest patients with follicular lymphoma should not receive rituximab maintenance therapy.
Hematology: Follicular lymphoma: maintenance therapy is (often) indicated
John F. Seymour
p624 | doi:10.1038/nrclinonc.2009.159
Maintenance therapy aims to sustain a state of ongoing disease remission. This article discusses the results of randomized trials that suggest that specific subgroups of patients with follicular lymphoma should receive maintenance therapy with rituximab.
Reviews
Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics
Ayalew Tefferi, Radek Skoda & James W. Vardiman
p627 | doi:10.1038/nrclinonc.2009.149
This Review discusses the criteria for the diagnosis and classification of myeloproliferative neoplasms in relation to the revised 2008 WHO classification. The authors summarize the histology of these tumors in the context of the 2008 WHO classification system, discuss associated cytogenetic and molecular abnormalcies of myeloproliferative neoplasms, and provide diagnostic algorithms that are tailored for routine clinical use.
Cyclophosphamide and cancer: golden anniversary
Ashkan Emadi, Richard J. Jones & Robert A. Brodsky
p638 | doi:10.1038/nrclinonc.2009.146
Cyclophosphamide is one of the most widely utilized chemotherapeutic and immunosuppressive agents in many combination chemotherapy regimens and autoimmune conditions. This Review highlights the chemistry, pharmacology, clinical toxic effects and current clinical applications of cyclophosphamide in cancer and autoimmune disorders. It also discusses the development of high-dose cyclophosphamide for blood and marrow transplantation and the treatment of autoimmune diseases.
New advances that enable identification of glioblastoma recurrence
Isaac Yang & Manish K. Aghi
p648 | doi:10.1038/nrclinonc.2009.150
After resection, malignant gliomas are routinely treated with adjuvant radiotherapy and temozolomide. The efficacy of these therapies has led to an increasing incidence of pseudoprogression and radiation necrosis, treatment-related effects that resemble tumor progression or recurrence on gadolinium-contrast MRI. The authors of this Review discuss the prognostic importance of accurate diagnosis of these post-treatment lesions, and the use of advanced imaging modalities for this purpose.
Chlamydial infection: the link with ocular adnexal lymphomas
Andrés J. M. Ferreri, Riccardo Dolcetti, Simone Magnino, Claudio Doglioni & Maurilio Ponzoni
p658 | doi:10.1038/nrclinonc.2009.147
Some lymphoma entities are associated with chronic bacterial infections. This Review discusses the association between Chlamydophila psittaci and ocular adnexal lymphoma. Prevalence, epidemiology and detection methods of C. psittaci infection along with therapeutic implications in ocular adnexal lymphoma are also discussed.
Case Study
Refractory neuroendocrine tumor—response to liposomal doxorubicin and capecitabine
Gianluca Masi, Lorenzo Fornaro, Samanta Cupini, Fotios Loupakis, Enrico Vasile, Giacomo G. Baldi, Irene Stasi, Lisa Salvatore & Alfredo Falcone
p670 | doi:10.1038/nrclinonc.2009.148
This Case Study describes a patient with metastatic typical carcinoid of the lung who had not responded to initial therapy with a somatostatin analog and chemotherapy (cisplatin and etoposide). She achieved an impressive and long-lasting response to the combination of capecitabine and lyposomal doxorubicin, without reporting any severe adverse effects. The authors discuss the diagnosis, examine differential diagnosis and briefly review the available treatment options in this setting.
Correspondence
Correspondence: Bortezomib and restoration of chemosensitivity
Alessandro Gozzetti
doi:10.1038/nrclinonc.2009.15-c1
Correspondence: Author reply: Bortezomib and restoration of chemosensitivity
Chor Sang Chim, Yu Yan Hwang, Clara Pang & Tony W. Shek
doi:10.1038/nrclinonc.2009.15-c2
